[Studies on josamycin. 3. (1) Bacteriological studies. (2) Protective effect against infections due to pathogenic bacteria. (3) Absorption, excretion, distribution in organs and in vivo activities].
D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D001412:Bacillus subtilis / Q000187:drug effects; D002701:Chloramphenicol / Q000627:therapeutic use; D003470:Culture Media; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007106:Immune Sera; D017053:Infection Control; D007933:Leucomycins / Q000494:pharmacology; D008297:Male; D051379:Mice; D009174:Mycoplasma / Q000187:drug effects; D011008:Pneumococcal Infections / Q000188:drug therapy; D011817:Rabbits; D051381:Rats; D012505:Sarcina / Q000187:drug effects; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects; D013302:Streptomyces
D000900:Anti-Bacterial Agents; D003470:Culture Media; D007106:Immune Sera; D007933:Leucomycins; D004917:Erythromycin; D002701:Chloramphenicol